Prioritizing Mental Health in South African Medical Schemes: Challenges and Opportunities

By HEOR Staff Writer

May 1, 2023

Medical schemes in South Africa are prioritizing mental health as a key component of managed care services. In 2019 CMS published a PMB definition guidelines for mental health emergencies.

“It is still concerning that beneficiaries of medical schemes attracted copayments as high as five (5%) for services such as a psychiatry benefit. Prior studies have also found that medical scheme members affected by mental illness and in most cases were discriminated against by funders. There needs to be a concerted effort to reprioritise mental health,” said Willie

A study analysed data from 2014-2018 and found the most prevalent mental disorders in South Africa in 2017 were anxiety and depression. However, only schizophrenia and bipolar mood disorder are the only conditions included in the PMB Chronic Diseases List (CDLs).

It is worrying that mental disorders like depression and anxiety are not covered under PMBs. We need a review of PMBs to include these conditions. A designated medical scheme provider should consider resource scarcity and co-payment rules.

Reference url

Recent Posts

EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy

By João L. Carapinha

March 17, 2026

Imfinzi gastric cancer treatment has received European Commission approval for adults with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. AstraZeneca’s Imfinzi (durvalumab), a PD-L1 inhibitor, combined with FLOT chemotherapy...
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Europe life sciences competitiveness is under pressure, as detailed in the EFPIA report "Asses...
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Agonists
This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucagon-like peptide-1 (GLP-1) receptor agonists for ty...